Skip to main content
54°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
330.64
+0.13 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
40
41
Next >
Looking At Amgen's Recent Unusual Options Activity
January 05, 2024
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
January 03, 2024
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.
Via
InvestorPlace
Amgen's Options: A Look at What the Big Money is Thinking
December 28, 2023
Via
Benzinga
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
December 25, 2023
Via
Benzinga
Is NASDAQ:AMGN a Good Fit for Dividend Investing?
December 22, 2023
Why AMGEN INC (NASDAQ:AMGN) is a Top Pick for Dividend Investors.
Via
Chartmill
Did Santa Claus Claus Leave Town A Day Early?
January 02, 2024
With the exception of the Dow, stocks are down hard to begin the new calendar year.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024
January 02, 2024
Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
January 01, 2024
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with.
Via
The Motley Fool
Topics
ETFs
Retirement
Exposures
Pension
Amgen Stock Sees Relative Strength Rating Improve To 74
December 29, 2023
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.
Via
Investor's Business Daily
Spotlight on Amgen: Analyzing the Surge in Options Activity
December 21, 2023
Via
Benzinga
Looking Into Amgen's Recent Short Interest
December 20, 2023
Via
Benzinga
In-Depth Examination Of 18 Analyst Recommendations For Amgen
December 19, 2023
Via
Benzinga
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
December 29, 2023
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
December 26, 2023
Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug
Via
Benzinga
Exposures
Product Safety
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
December 21, 2023
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
Via
InvestorPlace
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
December 20, 2023
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.
Via
InvestorPlace
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
December 19, 2023
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space.
Via
Benzinga
Is Amgen Stock a Buy Now?
December 17, 2023
Boring businesses can be successful, too.
Via
The Motley Fool
Market Whales and Their Recent Bets on AMGN Options
December 14, 2023
Via
Benzinga
Insights Into Amgen's Performance Versus Peers In Biotechnology Sector
December 11, 2023
Via
Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
December 19, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
December 18, 2023
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records.
Via
Talk Markets
1 Biotech Stock That Could Be the Next Amgen
December 13, 2023
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.
Via
The Motley Fool
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
December 12, 2023
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.
Via
The Motley Fool
P/E Ratio Insights for Amgen
December 06, 2023
Via
Benzinga
Looking Into Amgen's Recent Short Interest
November 30, 2023
Via
Benzinga
Analyst Ratings for Amgen
November 29, 2023
Via
Benzinga
PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
December 12, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.